Skip to main content
. 2009 May 18;83(3):547–557. doi: 10.1093/cvr/cvp153

Figure 4.

Figure 4

ERK activation is involved in enhanced growth/proliferation of HUVECs by silencing TRPM7. (A) Representative immunoblots showing increased phospho-ERK (left) or phospho-MEK1/2 (right) in HUVECs 72 h following the transfection of the indicated siRNAs. Bar graphs show densitometrically quantified ratio of phospho-ERK/β-actin (left) and phospho-MEK1/2/β-actin (right) in HUVECs transfected with or without control or TRPM7-siRNAs (n=3, *P < 0.05, **P < 0.01, control siRNA vs. TRPM7-siRNA1-treated cells. (B) Immonoblotting showing the lack of effect on phospho-p38 MARK and phospho-JNK by TRPM7-siRNA1. Third lane shows control siRNA-treated cells incubated with 20 ng/ml TNFα (for 15 min) as a positive control. (C) Treatment of HUVECs with ERK inhibitor U0126 (10 or 30 µmol/L) attenuated or prevented enhancement of growth/proliferation by TRPM7-siRNA1. n = 7–11. **P < 0.01, control vs. TRPM7-siRNA1-treated cells, ##P < 0.01, U0126 untreated vs. treated cells.